Pulmatrix, Inc. (PULM)

You are trying to access subscriber-only content.

If you are a subscriber, log in here.

If you are not a subscriber, click here for your subscription. Subscribers will have unlimited access to our magazine articles and more!

Article Excerpt

Stonegate Capital Partners just initiated coverage on this biotech company. Pulmatrix, Inc. (PULM) From The Konlin Letter Pulmatrix, Inc. (PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. PULM’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with […]

Comments

You must be logged in to post a comment.